Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Audio By Carbonatix

LONDON--(BUSINESS WIRE)--Nov 12, 2025--

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 8:00 a.m. ET (1:00 p.m. GMT).

The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251112215352/en/

CONTACT: Inquiries:Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

[email protected]

Tel: +1 (646) 637-3208

KEYWORD: EUROPE IRELAND UNITED KINGDOM

INDUSTRY KEYWORD: RESEARCH CARDIOLOGY BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH OTHER SCIENCE SCIENCE

SOURCE: Silence Therapeutics plc

Copyright Business Wire 2025.

PUB: 11/12/2025 08:00 AM/DISC: 11/12/2025 08:01 AM

http://www.businesswire.com/news/home/20251112215352/en